and FDA staffing decisions at a Senate hearing. EU says Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation Catalent does not pose antitrust issues.

The growing incidence of genetic disorders and chronic illnesses, including cancer and rare inherited conditions, is fueling the demand for advanced therapies, highlighting the need for strong ...

“The agreement to acquire the three Catalent manufacturing sites ... Neurotech Pharma's cell therapy Encelto has become the first FDA-approved therapy for idiopathic macular telangiectasia ...

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

February 22, 2025 Exclusive: US FDA asks fired scientists to return ... Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus Novo Holdings, the controlling ...